Vistagen Therapeutics (VTGN) EBT (2011 - 2026)
Vistagen Therapeutics (VTGN) posted EBT of -$16.3 million for Q1 2026, up 13.81% sequentially from -$18.9 million in Q4 2025, and down 19.56% YoY from -$20.3 million in Q1 2025.
Vistagen Therapeutics (VTGN) EBT (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported EBT for 15 years, with the latest figure at -$16.3 million in Q1 2026.
- Quarterly EBT fell 19.56% year-over-year to -$16.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$69.7 million (down 35.6% YoY) and the FY2026 annual result came in at -$69.7 million, down 35.6% from the prior year.
- EBT improved to -$16.3 million in Q1 2026 per VTGN's latest filing, from -$18.9 million in the prior quarter.
- Over five years, EBT peaked at -$6.4 million in Q4 2023 and troughed at -$19.8 million in Q2 2022.
- A 5-year average of -$13.3 million and a median of -$13.6 million in 2025 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2023: EBT sank 168.68% in 2022, then soared 65.1% in 2023.
- Over 5 years, EBT stood at -$9.8 million in 2022, then jumped by 34.95% to -$6.4 million in 2023, then sank by 121.87% to -$14.1 million in 2024, then slumped by 34.14% to -$18.9 million in 2025, then advanced by 13.81% to -$16.3 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$16.3 million, -$18.9 million, and -$19.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Vistagen Therapeutics | 10.35 Mn | 10.35 Mn | - | -13.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.29 Mn |
| Dec 31, 2025 | -18.90 Mn |
| Sep 30, 2025 | -19.42 Mn |
| Jun 30, 2025 | -15.10 Mn |
| Mar 31, 2025 | -13.62 Mn |
| Dec 31, 2024 | -14.09 Mn |
| Sep 30, 2024 | -12.95 Mn |
| Jun 30, 2024 | -10.73 Mn |
| Mar 31, 2024 | -9.52 Mn |
| Dec 31, 2023 | -6.35 Mn |
| Sep 30, 2023 | -6.59 Mn |
| Jun 30, 2023 | -6.90 Mn |
| Mar 31, 2023 | -12.23 Mn |
| Dec 31, 2022 | -9.76 Mn |
| Sep 30, 2022 | -17.48 Mn |
| Jun 30, 2022 | -19.77 Mn |
| Mar 31, 2022 | -16.69 Mn |
| Dec 31, 2021 | -10.53 Mn |
| Sep 30, 2021 | -12.80 Mn |
| Jun 30, 2021 | -7.74 Mn |